# Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

> **NCT03170180** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 66 (actual)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Gefitinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT03170180
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-12-28
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03170180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03170180, "Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03170180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*